We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pediatrix Medical Refills Its Buyback Prescription With $250M Dose
Read MoreHide Full Article
Key Takeaways
Pediatrix authorized a $250M share buyback after generating $245M in operating cash flow in TTM.
The company raised 2025 adjusted EBITDA guidance to $245-$255M from $220-$240M.
Profitability improved with divestitures, boosting return on capital to 10.6%.
Pediatrix Medical Group, Inc. (MD - Free Report) has stepped up its commitment to shareholder returns with a new $250 million share repurchase authorization, underpinned by solid cash generation. Over the past 12 months, the company produced $245 million in operating cash flow, marking an 18.4% year-over-year increase.
In the first half of 2025, Pediatrix repurchased $1.8 million worth of common stock and had a leftover capacity of $1.1 million under its previous program, which had been in place since 2018. The expanded authorization gives management fresh flexibility to enhance shareholder value going forward.
At the end of second-quarter 2025, Pediatrix held $224.7 million in cash and cash equivalents, slightly down 2.3% from 2024-end, while total debt stood at $607.5 million, a 1.6% reduction from December levels. Its long-term debt-to-capital ratio of 42.2% remains below the industry average of 43.7%, reflecting disciplined balance sheet management.
Profitability has strengthened thanks to the divestiture of lower-margin, non-core assets, allowing the company to concentrate on its core physician services. Return on capital now stands at 10.6%, comfortably above the industry average of 7.4%.
Operational momentum is also evident. Higher patient volumes, improved acuity, favorable collections and reduced operating expenses are lifting performance. Management now expects 2025 adjusted EBITDA in the range of $245-$255 million compared with its earlier projection of $220-$240 million. With healthier fundamentals, improved efficiency and a sizable repurchase authorization, Pediatrix is positioning itself for stronger shareholder rewards in the coming days.
How Are MD’s Peers Faring in the Repurchase Front?
Bigger companies in the healthcare space, like HCA Healthcare, Inc. (HCA - Free Report) and Universal Health Services, Inc. (UHS - Free Report) , are also returning capital to shareholders through strong buyback programs.
HCA Healthcare bought back shares worth $2.5 billion in the second quarter alone. It had a leftover capacity of $5.8 billion under its authorization as of June 30. HCA Healthcare generated $5.9 billion in cash flow from operations in the first half of 2025, up 32% year over year.
Universal Health bought back shares worth $150.8 million in the second quarter. It had a leftover repurchase capacity of around $492.9 million as of the second-quarter end. Universal Health generated operating cash flow of $549 million in the second quarter of 2025, down 19.2% from the year-ago level.
Pediatrix Medical’s Price Performance, Valuation and Estimates
Shares of Pediatrix Medical have gained 21.9% year to date, outperforming the broader industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Pediatrix Medical trades at a forward price-to-earnings ratio of 9.54X, below the industry average of 15.08X. MD carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Pediatrix Medical’s 2025 earnings implies a 14.6% increase year over year, followed by 3.2% growth next year.
Image: Bigstock
Pediatrix Medical Refills Its Buyback Prescription With $250M Dose
Key Takeaways
Pediatrix Medical Group, Inc. (MD - Free Report) has stepped up its commitment to shareholder returns with a new $250 million share repurchase authorization, underpinned by solid cash generation. Over the past 12 months, the company produced $245 million in operating cash flow, marking an 18.4% year-over-year increase.
In the first half of 2025, Pediatrix repurchased $1.8 million worth of common stock and had a leftover capacity of $1.1 million under its previous program, which had been in place since 2018. The expanded authorization gives management fresh flexibility to enhance shareholder value going forward.
At the end of second-quarter 2025, Pediatrix held $224.7 million in cash and cash equivalents, slightly down 2.3% from 2024-end, while total debt stood at $607.5 million, a 1.6% reduction from December levels. Its long-term debt-to-capital ratio of 42.2% remains below the industry average of 43.7%, reflecting disciplined balance sheet management.
Profitability has strengthened thanks to the divestiture of lower-margin, non-core assets, allowing the company to concentrate on its core physician services. Return on capital now stands at 10.6%, comfortably above the industry average of 7.4%.
Operational momentum is also evident. Higher patient volumes, improved acuity, favorable collections and reduced operating expenses are lifting performance. Management now expects 2025 adjusted EBITDA in the range of $245-$255 million compared with its earlier projection of $220-$240 million. With healthier fundamentals, improved efficiency and a sizable repurchase authorization, Pediatrix is positioning itself for stronger shareholder rewards in the coming days.
How Are MD’s Peers Faring in the Repurchase Front?
Bigger companies in the healthcare space, like HCA Healthcare, Inc. (HCA - Free Report) and Universal Health Services, Inc. (UHS - Free Report) , are also returning capital to shareholders through strong buyback programs.
HCA Healthcare bought back shares worth $2.5 billion in the second quarter alone. It had a leftover capacity of $5.8 billion under its authorization as of June 30. HCA Healthcare generated $5.9 billion in cash flow from operations in the first half of 2025, up 32% year over year.
Universal Health bought back shares worth $150.8 million in the second quarter. It had a leftover repurchase capacity of around $492.9 million as of the second-quarter end. Universal Health generated operating cash flow of $549 million in the second quarter of 2025, down 19.2% from the year-ago level.
Pediatrix Medical’s Price Performance, Valuation and Estimates
Shares of Pediatrix Medical have gained 21.9% year to date, outperforming the broader industry.
From a valuation standpoint, Pediatrix Medical trades at a forward price-to-earnings ratio of 9.54X, below the industry average of 15.08X. MD carries a Value Score of A.
The Zacks Consensus Estimate for Pediatrix Medical’s 2025 earnings implies a 14.6% increase year over year, followed by 3.2% growth next year.
The stock currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.